| 20.08 14:09 | dpa-AFX: Johnson & Johnson To Acquire V-Wave For Initial Payment Of $600 Mln |
| 20.08 13:51 | dpa-AFX: Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod |
| 20.08 13:38 | dpa-AFX: *JOHNSON & JOHNSON EXPECTS V-WAVE TRANSACTION TO DILUTE ADJ. EPS BY $0.24 IN 2024 AND $0.06 IN 2025 |
| 20.08 13:37 | dpa-AFX: *JOHNSON & JOHNSON - V-WAVE DEAL EXPECTED TO CLOSE BEFORE END OF 2024 |
| 20.08 13:35 | dpa-AFX: *JOHNSON & JOHNSON TO ACQUIRE V-WAVE FOR $600 MLN UPFRONT, WITH POTENTIAL FOR $1.1 BLN IN MILESTONE PAYMENTS |
| 20.08 13:05 | dpa-AFX: *JOHNSON & JOHNSON:FDA APPROVES RYBREVANT+LAZCLUZE FOR 1ST-LINE TREATMENT OF ADULTS WITH EGFR-MUTATED LUNG CANCER |
| 16.08 12:28 | MARKT USA/Wall Street nach Rally behauptet erwartet |
| 16.08 10:31 | US-Regierung/Pharmakonzerne einigen sich auf niedrigere Medikamentenpreise |
| 31.07 05:34 | dpa-AFX: Johnson & Johnson : FDA Approves Darzalex Faspro Combination For Multiple Myeloma |
| 26.07 15:55 | dpa-AFX: J&J: CHMP Recommends RYBREVANT With Chemo To Treat Advanced EGFR-mutated NSCLC |
| 26.07 14:47 | dpa-AFX: *CHMP RECOMMENDS J&J'S RYBREVANT WITH CHEMO FOR ADVANCED EGFR-MUTATED NSCLC |
| 26.07 14:19 | dpa-AFX: Johnson & Johnson's Yuvanci Gets Positive CHMP Opinion In Europe For Pulmonary Arterial Hypertension |
| 26.07 13:52 | dpa-AFX: *JOHNSON & JOHNSON GETS POSITIVE CHMP OPINION FOR YUVANCI IN PULMONARY ARTERIAL HYPERTENSION |
| 22.07 14:18 | dpa-AFX: Johnson & Johnson Seeks FDA Approval For SPRAVATO Nasal Spray For Treatment-Resistant Depression |
| 22.07 14:02 | dpa-AFX: *JOHNSON & JOHNSON SEEKS FDA APPROVAL OF SPRAVATO AS ONLY MONOTHERAPY FOR ADULTS WITH TREATMENT-RESISTANT DEPRESSION |
| 17.07 22:36 | MÄRKTE USA/Drohende neue Handelsbeschränkungen belasten Chipsektor |
| 17.07 22:12 | MÄRKTE USA/Drohende neue Handelsbeschränkungen belasten Chipsektor |
| 17.07 18:35 | MÄRKTE USA/Unsicherheit über künftige Wirtschaftspolitik belastet |
| 17.07 16:52 | dpa-AFX: ROUNDUP 2/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 16:52 | ROUNDUP 2/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
|
|
